Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial

被引：0
|
作者：
Preiss, David [1 ]
Herrington, William [1 ]
Haynes, Richard [1 ]
机构：
[1] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England
来源：
CIRCULATION | 2022年 / 146卷 / 25期
关键词：
Sodium glucose co-transporter 2 inhibitors Chronic kidney disease; Cardiovascular disease Clinical trials;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
19464
引用
收藏
页码：E577 / E577
页数：1
相关论文
共 50 条
  • [21] EFFECTS OF EMPAGLIFLOZIN ON KIDNEY AND CARDIACMRI MEASURES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Judge, Parminder
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I48 - I49
  • [22] Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure Insights From the EMPA-REG OUTCOME Trial
    Butler, Javed
    Zannad, Faiez
    Fitchett, David
    Zinman, Bernard
    Koitka-Weber, Audrey
    von Eynatten, Maximilian
    Zwiener, Isabella
    George, Jyothis
    Brueckmann, Martina
    Cheung, Alfred K.
    Wanner, Christoph
    CIRCULATION-HEART FAILURE, 2019, 12 (06)
  • [23] Empagliflozin and kidney outcomes in patients with or without heart failure at baseline: insights from the EMPA-REG OUTCOME trial
    Butler, J.
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    DIABETOLOGIA, 2018, 61 : S323 - S323
  • [24] A phase III trial of empagliflozin in patients with Type 2 diabetes with stage 2 or 3 chronic kidney disease (EMPA-REG RENAL™)
    Barnett, A. H.
    Mithal, A.
    Manassie, J.
    Jones, R.
    Rattunde, H.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2014, 31 : 63 - 63
  • [25] Dapagliflozin versus empagliflozin in patients with chronic kidney disease
    Alnsasra, Hilmi
    Tsaban, Gal
    Solomon, Adam
    Khalil, Fouad
    Aboalhasan, Enis
    Azab, Abed N.
    Azuri, Joseph
    Hammerman, Ariel
    Arbel, Ronen
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [26] Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease
    Mann, Johannes F. E.
    Joseph, Philip
    Gao, Peggy
    Pais, Prem
    Tyrwhitt, Jessica
    Xavier, Denis
    Dans, Tony
    Jaramillo, Patricio Lopez
    Gamra, Habib
    Yusuf, Salim
    KIDNEY INTERNATIONAL, 2023, 103 (02) : 403 - 410
  • [27] Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease
    Neuen, Brendon L.
    Ohkuma, Toshiaki
    Neal, Bruce
    Matthews, David R.
    Mahaffey, Kenneth W.
    Fulcher, Greg
    Desai, Mehul
    Li, Qiang
    Deng, Hsiaowei
    Rosenthal, Norm
    Jardine, Meg
    Bakris, George
    Perkovic, Vlado
    DIABETES, 2018, 67
  • [28] Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients
    Goto, Hirohito
    Iseri, Ken
    Hida, Noriko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (06) : 1016 - 1022
  • [29] The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
    Herrington, William G.
    Preiss, David
    Haynes, Richard
    von Eynatten, Maximilian
    Staplin, Natalie
    Hauske, Sibylle J.
    George, Jyothis T.
    Green, Jennifer B.
    Landray, Martin J.
    Baigent, Colin
    Wanner, Christoph
    CLINICAL KIDNEY JOURNAL, 2018, 11 (06) : 749 - 761
  • [30] Empagliflozin (Jardiance) for Chronic Kidney Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1689): : 183 - 184
12345